Abstract:Antibody-based drugs have attracted much attention for their targeting ability, high efficacy and low toxicity. But it is difficult for those intrabodies, a kind of antibody whose targets are intracellular biomarkers, to become effective drugs due to the lack of intracellular delivery strategy and their short circulation time in blood. Human telomerase reverse transcriptase (hTERT), an important biomarker for tumors, is expressed only in cytoplasm instead of on cell membrane. In this study, the anti-hTERT blocking monoclonal antibody (mAb), as the model intrabody, was used to prepare nanoparticles (NPs), followed by the encapsulation of erythrocyte membrane (EM), to obtain the EM-coated anti-hTERT mAb NPs delivery system. The final NPs showed a z-average hydrodynamic diameter of about 197.3 nm. The in vitro cellular uptake by HeLa cells confirmed that compared with free anti-hTERT mAb, the EM-coated anti-hTERT mAb NPs exhibited a significantly increased uptake by tumor cells. Besides, the pharmacokinetic study confirmed that the EM encapsulation can remarkably prolong the circulation time and increase the area under curve (AUC) of NPs in blood. The EM-coated anti-hTERT mAb NPs exhibited a remarkably decreased uptake by macrophages than uncoated NPs, which may be responsible for the prolonged circulation time and increased AUC. Furthermore, the frozen section of tumor tissue was performed and proved that the EM-coated anti-hTERT mAb NPs can be more effectively accumulated in tumor tissues than the free mAb and uncoated NPs. In summary, this study indicated that EM-coated anti-hTERT mAb NPs are an effective delivery system for the long circulation and intracellular delivery of an intrabody, and make it possible for the intracellular biomarkers to become the potential targets of drugs.

Antibody-Free Glycogen Nanoparticles Engage Human Immune T Cells for Intracellular Delivery of Small Drugs or mRNA

Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery

The Recognition of and Reactions to Nucleic Acid Nanoparticles by Human Immune Cells

Lipid nanoparticle-mediated RNA delivery for immune cell modulation

Antibody-Loading of Biological Nanocarrier Vesicles Derived from Red-Blood-Cell Membranes

Nanomaterials trigger functional responses in primary human immune cells

Expanding Structural Space for Immunomodulatory Nucleic Acid Nanoparticles (Nanps) via Spatial Arrangement of Their Therapeutic Moieties

Glycogen nanoparticles for efficient mRNA transduction to T lymphocytes

Supramolecular Glyco-Nanoparticles Toward Immunological Applications

Nanoparticles that Transcytosed through Cancer Cells Can Elicit Immune Response

Antigen-specific T cell immunotherapy by in vivo mRNA delivery

Therapeutic immunomodulation by rationally designed nucleic acids and nucleic acid nanoparticles

Nucleic acid nanoparticles (NANPs) as molecular tools to direct desirable and avoid undesirable immunological effects

Nano-drug delivery systems for T cell-based immunotherapy

Antigen-specific nanomedicines for the treatment of autoimmune disease: target cell types, mechanisms and outcomes

An Effective Intracellular Delivery System of Monoclonal Antibody for Treatment of Tumor: Erythrocyte Membrane-coated Self-associated Antibody Nanoparticles.

Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis

An Antibody-like Polymeric Nanoparticle Removes Intratumoral Galectin-1 to Enhance Antitumor T-Cell Responses in Cancer Immunotherapy.

Polymeric nanoparticle gel for intracellular mRNA delivery and immunological reprogramming of tumors

Engineered Cell-Membrane-Coated Nanoparticles Directly Present Tumor Antigens to Promote Anticancer Immunity.